Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
F10 encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. De plus, nous expédions Coagulation Factor X Kits (55) et Coagulation Factor X Protéines (23) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 121 products:
Human Polyclonal Coagulation Factor X Primary Antibody pour EIA, WB - ABIN452984
Alba, Bradshaw, Parker, Bhella, Waddington, Nicklin, van Rooijen, Custers, Goudsmit, Barouch, McVey, Baker: Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. dans Blood 2009
Show all 3 references for ABIN452984
Human Polyclonal Coagulation Factor X Primary Antibody pour ELISA, WB - ABIN1536116
Messier, Pittman, Long, Kaufman, Church: Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X. dans Gene 1991
Show all 2 references for ABIN1536116
Human Polyclonal Coagulation Factor X Primary Antibody pour ELISA, WB - ABIN1536097
Leytus, Foster, Kurachi, Davie: Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. dans Biochemistry 1986
Show all 2 references for ABIN1536097
Human Polyclonal Coagulation Factor X Primary Antibody pour ELISA - ABIN1998177
Rosen: Gene targeting in hemostasis. Factor X. dans Frontiers in bioscience : a journal and virtual library 2002
Human Monoclonal Coagulation Factor X Primary Antibody pour EIA, WB - ABIN951606
Suvarna, Rauova, McCracken, Goss, Sachais, McKenzie, Reilly, Gunn, Cines, Poncz, Arepally: PF4/heparin complexes are T cell-dependent antigens. dans Blood 2005
Cow (Bovine) Polyclonal Coagulation Factor X Primary Antibody pour WB - ABIN2776973
Hsu, Tsai, Sun, Chang, Huang, Yu, Lin, Mao, Yang: Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling. dans The Journal of biological chemistry 2008
Enhanced FXa and PAR2 (Montrer F2RL1 Anticorps) exacerbate DN and that both are promising targets for preventing diabetic nephropathy.
Macrophages regulate FX plasma levels in an SR-AI (Montrer MSR1 Anticorps)-dependent manner.
Factor Xa has a role in inhibiting HMGB1 (Montrer HMGB1 Anticorps)-induced septic responses in human umbilical vein endothelial cells and in mice
Selective inhibition of FXa improves the left ventricular function during CVB3-induced myocarditis and seems to be associated with an improved myocardial remodeling.
Activated factor X signaling via protease-activated receptor 2 (Montrer F2RL1 Anticorps) suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells.
There was no detectable increase in plasma levels of mouse FX after active-site inhibited human APC (Montrer APC Anticorps) administration to mice overexpressing human EPCR (Montrer PROCR Anticorps). FX does not effectively interact with EPCR (Montrer PROCR Anticorps) in vivo, at least in regards to the mouse system.
investigation of role of F10a in progression of diabetic nephropathy: data from studies using inhibitor of F10a suggest that F10a does play a role in development of proteinemia, glomerular hypertrophy, and protein deposition in kidney of db/db (Montrer LEPR Anticorps) mice
Data suggest that tissue factor (Montrer F3 Anticorps) and factor V induction by LPS (Montrer TLR4 Anticorps) may in part accelerate mesangioproliferative glomerulonephritis through activation of factor X and downstream proinflammatory and procoagulant mechanisms.
Gene targeting of tissue factor (Montrer F3 Anticorps), factor X, and factor VII (Montrer TH Anticorps) in mice: their involvement in embryonic development
Factor Xa functions in airway remodeling in asthma by stimulating mucin (Montrer SLC13A2 Anticorps) production, through regulation of amphiregulin (Montrer AREG Anticorps) expression and collagen deposition.
Individuals suffering from relapsing-remitting and secondary progressive multiple sclerosis had significantly higher prothrombin (Montrer F2 Anticorps) and factor X levels than healthy donors, whereas levels were unchanged in primary progressive MS and neuromyelitis optica patients.
Low concentrations of TF and exogenous FXIa, each too low to elicit a burst in thrombin (Montrer F2 Anticorps) production alone, act synergistically when in combination to cause substantial thrombin (Montrer F2 Anticorps) production.
analysis of how physiological concentrations of Tissue factor pathway inhibitor (Montrer TFPI Anticorps) inhibit FXa
According to our study, compounds 1a, 1g and 1s displayed evident FXa inhibitory activity and excellent selectivity over thrombin (Montrer F2 Anticorps) in in vitro inhibition activities studies.
Large deletions play a minor but essential role in the mutational spectrum of the F7 and F10 genes. Copy number analyses (e. g. MLPA) should be considered if sequencing cannot clarify the underlying reason of an observed coagulopathy. Of note, in cases of combined FVII (Montrer F7 Anticorps)/FX deficiency, a deletion of the two contiguous genes might be part of a larger chromosomal rearrangement.
homozygous mutation g.27881G>A(p.Val298Met) of the F10 gene has been identified, which probably accounts for the low FX concentrations in this pedigree
Establish FXa as a potentially important asthma mediator, stimulating airway smooth muscle function through actions requiring PAR-1 (Montrer MARK2 Anticorps) and annexin A2 (Montrer ANXA2 Anticorps) and involving integrin coactivation.
FXa may inhibit lipopolysaccharide-mediated expression of sPLA2-IIA (Montrer PLA2G2A Anticorps) by suppression of cytosolic phospholipase A2 (Montrer PLA2G4A Anticorps) and extracellular signal-regulated kinase 1/2 (Montrer MAPK3 Anticorps).
Several members of a family had a c.112 G>C mutation in exon 2 of the F10 gene. Although in-silico analysis predicts this is a benign mutation, this family suggests that the amino acid substitution affects the properties of the factor X protein.
Various acylcarnitines inhibited factor Xa-initiated clotting.
Data suggest factor Xa (FXa) and factor Va (FVa) compete to bind FXa on both PS model membranes and microparticles from activated platelets; this competition between dimerization/prothrombinase (Montrer FGL2 Anticorps) complex formation appears to regulate blood coagulation.
thrombin (Montrer F2 Anticorps) and factor Xa diffusion along the heparin molecule explains the effects of extended heparin chain lengths
Factor Xa (fXa), a key serine protease (Montrer F2 Anticorps) of the coagulation system, was used as a model enzyme to test the canonical conformation hypothesis.
This gene encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. This factor undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds\; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity.
coagulation factor 10
, coagulation factor X
, vitamin K dependent serine protease
, coagulation factor X preproprotein
, Coagulation factor X
, stuart factor
, Stuart-Prower factor
, factor Xa
, blood coagulation factor X
, factor XA light chain
, virus activating protease
, virus-activating protease